MedTrace Logo

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-06-08

No results posted yet for this study

Summary

The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).

The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months.

Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigational new drug research study.

Conditions

Interventions

DRUG

Bazedoxifene Acetate

40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules

Sponsors & Collaborators

  • Riley Bove, MD

    lead OTHER

Principal Investigators

  • Riley M Bove, MD MMSc · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2025-05-13
Completion
2025-05-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04002934 on ClinicalTrials.gov